CoChat

Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase-deficient children receiving dapsone

Pamba, Allan, Richardson, Naomi D., Carter, Nick, Duparc, Stephan, Premji, Zul, Tiono, Alfred B., Luzzatto, Lucio · 2012 · Blood
Cited by 104

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Drug-induced acute hemolytic anemia led to the discovery of G6PD deficiency. However, most clinical data are from isolated case reports. In 2 clinical trials of antimalarial preparations containing dapsone (4,4′-diaminodiphenylsulfone; 2.5 mg/kg once daily for 3 days), 95 G6PD-deficient hemizygous boys, 24 G6PD-deficient homozygous girls, and 200 girls heterozygous for G6PD deficiency received this agent. In the first 2 groups, there was a maximum decrease in hemoglobin averaging −2.64 g/dL (range −6.70 to +0.30 g/dL), which was significantly greater than for the comparator group receiving artemether-lumefantrine (adjusted difference −1.46 g/dL; 95% confidence interval −1.76, −1.15). Hemoglobin concentrations were decreased by ≥ 40% versus pretreatment in 24/119 (20.2%) of the G6PD-deficient children; 13/119 (10.9%) required blood transfusion. In the heterozygous girls, the mean maximum decrease in hemoglobin was −1.83 g/dL (range +0.90 to −5.20 g/dL); 1 in 200 (0.5%) required blood transfusion. All children eventually recovered. All the G6PD-deficient children had the G6PD A− variant, ie, mutations V68M and N126D. Drug-induced acute hemolytic anemia in G6PD A− subjects can be life-threatening, depending on the nature and dosage of the drug trigger. Therefore, contrary to current perception, in clinical terms the A− type of G6PD deficiency cannot be regarded as mild. This study is registered at http://www.clinicaltrials.gov as NCT00344006 and NCT00371735.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2012-03-416032

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 45

  1. Luzzatto, 1979, Genetics of red cells and susceptibility to malaria., Blood, 54, 961, 10.1182/blood.V54.5.961.bloodjournal545961 · doi:10.1182/blood.v54.5.961.bloodjournal545961
  2. Luzzatto, 2001, Malaria. Protecting against bad air., Science, 293, 442, 10.1126/science.1063292 · DOI
  3. Motulsky, 1960, Metabolic polymorphisms and the role of infectious diseases in human evolution., Hum Biol, 32, 28
  4. Nkhoma, 2009, The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis., Blood Cells Mol Dis, 42, 267, 10.1016/j.bcmd.2008.12.005 · DOI · Paper page
  5. Saunders, 2002, Nucleotide variability at G6pd and the signature of malarial selection in humans., Genetics, 162, 1849, 10.1093/genetics/162.4.1849 · DOI · Paper page
  6. Bienzle, 1972, Glucose-6-phosphate dehydrogenase and malaria. Greater resistance of females heterozygous for enzyme deficiency and of males with non-deficient variant., Lancet, 1, 107, 10.1016/S0140-6736(72)90676-9 · DOI · Paper page
  7. Clark, 2009, Allelic heterogeneity of G6PD deficiency in West Africa and severe malaria susceptibility., Eur J Hum Genet, 17, 1080, 10.1038/ejhg.2009.8 · DOI · Paper page
  8. Luzzatto, 2010, Glucose-6-phosphate dehydrogenase (G6PD) deficiency., 4473, 10.1093/med/9780199204854.003.220512 · doi:10.1093/med/9780199204854.003.220512
  9. Luzzatto, 2009, Glucose 6-phosphate dehydrogenase deficiency., 883
  10. Alving, 1956, Enzymatic deficiency in primaquine-sensitive erythrocytes., Science, 124, 484, 10.1126/science.124.3220.484-a · DOI · Paper page
  11. Beutler, 1959, The hemolytic effect of primaquine and related compounds: a review., Blood, 14, 103, 10.1182/blood.V14.2.103.103 · DOI · Paper page
  12. Youngster, 2010, Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review., Drug Saf, 33, 713, 10.2165/11536520-000000000-00000 · DOI · Paper page
  13. Winstanley, 2001, Chlorproguanil-dapsone (LAPDAP) for uncomplicated falciparum malaria., Trop Med Int Health, 6, 952, 10.1046/j.1365-3156.2001.00751.x · DOI
  14. Alloueche, 2004, Comparison of chlorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double-blind randomised controlled trial., Lancet, 363, 1843, 10.1016/S0140-6736(04)16350-2 · DOI
  15. Luzzatto, 2010, The rise and fall of the antimalarial Lapdap: a lesson in pharmacogenetics., Lancet, 376, 739, 10.1016/S0140-6736(10)60396-0 · DOI
  16. Ponnampalam, 1981, Haemoglobinuria after a single dose treatment with dapsone and pyrimethamine for falciparum malaria in a patient with glucose-6-phosphate dehydrogenase deficiency., Trop Geogr Med, 33, 401
  17. Degowin, 1966, The haemolytic effects of diaphenylsulfone (DDS) in normal subjects and in those with glucose-6-phosphate-dehydrogenase deficiency., Bull World Health Organ, 35, 165
  18. Premji, 2009, Chlorproguanil-dapsone-artesunate versus artemether-lumefantrine: a randomized, double-blind phase III trial in African children and adolescents with uncomplicated Plasmodium falciparum malaria., PLoS One, 4, e6682, 10.1371/journal.pone.0006682 · DOI
  19. Tiono, 2009, Chlorproguanil-dapsone-artesunate versus chlorproguanil-dapsone: a randomized, double-blind, phase III trial in African children, adolescents, and adults with uncomplicated Plasmodium falciparum malaria., Am J Trop Med Hyg, 81, 969, 10.4269/ajtmh.2009.09-0351 · DOI
  20. Carter, 2011, Frequency of glucose-6-phosphate dehydrogenase deficiency in malaria patients from six African countries enrolled in two randomized anti-malarial clinical trials., Malar J, 10, 241, 10.1186/1475-2875-10-241 · DOI · Paper page
  21. Rasheed, 2009, Clinical and laboratory findings in acute malaria caused by various plasmodium species., J Pak Med Assoc, 59, 220
  22. Fischer, 1985, Membrane cross bonding in red cells in favic crisis: a missing link in the mechanism of extravascular haemolysis., Br J Haematol, 59, 159, 10.1111/j.1365-2141.1985.tb02976.x · DOI
  23. Vulliamy, 2003, Glucose-6-phosphate dehydrogenase deficiency and related disorders., 1921
  24. Beutler, 1954, The hemolytic effect of primaquine. IV. The relationship of cell age to hemolysis., J Lab Clin Med, 44, 439
  25. Dern, 1954, The hemolytic effect of primaquine. II. The natural course of the hemolytic anemia and the mechanism of its self-limited character., J Lab Clin Med, 44, 171
  26. Beutler, 1989, Molecular heterogeneity of glucose-6-phosphate dehydrogenase A., Blood, 74, 2550, 10.1182/blood.V74.7.2550.2550 · DOI · Paper page
  27. Goulart, 2002, Adverse effects of multidrug therapy in leprosy patients: a five-year survey at a Health Center of the Federal University of Uberlandia [in Portuguese]., Rev Soc Bras Med Trop, 35, 453, 10.1590/S0037-86822002000500005 · doi:10.1590/s0037-86822002000500005
  28. Deps, 2007, Adverse effects from multi-drug therapy in leprosy: a Brazilian study., Lepr Rev, 78, 216, 10.47276/lr.78.3.216 · doi:10.47276/lr.78.3.216
  29. Singh, 2011, Adverse effects of multi-drug therapy in leprosy, a two years' experience (2006-2008) in tertiary health care centre in the tribal region of Chhattisgarh state (Bastar, Jagdalpur)., Lepr Rev, 82, 17, 10.47276/lr.82.1.17 · doi:10.47276/lr.82.1.17
  30. Gill, 1995, N-hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity., Br J Clin Pharmacol, 40, 531, 10.1111/j.1365-2125.1995.tb05797.x · DOI
  31. Coleman, 1989, Bioactivation of dapsone to a cytotoxic metabolite by human hepatic microsomal enzymes., Br J Clin Pharmacol, 28, 389, 10.1111/j.1365-2125.1989.tb03517.x · DOI
  32. Bordin, 2010, Dapsone hydroxylamine induces premature removal of human erythrocytes by membrane reorganization and antibody binding., Br J Pharmacol, 161, 1186, 10.1111/j.1476-5381.2010.00962.x · DOI
  33. Nance, 1964, Genetic tests with a sex-linked marker: glucose-6-phosphate dehydrogenase., Cold Spring Harb Symp Quant Biol, 29, 415, 10.1101/SQB.1964.029.01.043 · DOI
  34. Rinaldi, 1976, Variability of red cell phenotypes between and within individuals in an unbiased sample of 77 heterozygotes for G6PD deficiency in Sardinia., Am J Hum Genet, 28, 496
  35. Meloni, 1983, Favism and hemolytic anemia in glucose-6-phosphate dehydrogenase–deficient subjects in North Sardinia., Acta Haematol, 70, 83, 10.1159/000206700 · DOI
  36. Cui, 2009, Discovery, mechanisms of action and combination therapy of artemisinin., Expert Rev Anti Infect Ther, 7, 999, 10.1586/eri.09.68 · DOI · Paper page
  37. Selmeczi, 2004, Alkylation of human hemoglobin A0 by the antimalarial drug artemisinin., FEBS Lett, 556, 245, 10.1016/S0014-5793(03)01448-0 · DOI
  38. Corpolongo, 2012, Haemolytic anaemia in an HIV-infected patient with severe falciparum malaria after treatment with oral artemether-lumefantrine., Malar J, 11, 91, 10.1186/1475-2875-11-91 · DOI
  39. Jalloh, 2004, Rapid epidemiologic assessment of glucose-6-phosphate dehydrogenase deficiency in malaria-endemic areas in Southeast Asia using a novel diagnostic kit., Trop Med Int Health, 9, 615, 10.1111/j.1365-3156.2004.01237.x · DOI
  40. Betke, 1967, Standardization of procedures for the study of glucose-6-phosphate dehydrogenase: report of a WHO Scientific Group., World Health Org Tech Rep Ser, 366, 5
  41. Salvidio, 1972, Hemolytic side effects on some antimalarial drugs., Proc Hemlinth Soc Washington, 39, 83
  42. Odièvre, 2011, Unsuspected glucose-6-phosphate dehydrogenase deficiency presenting as symptomatic methemoglobinemia with severe hemolysis after fava bean ingestion in a 6-year-old boy., Int J Hematol, 93, 664, 10.1007/s12185-011-0827-6 · doi:10.1007/s12185-011-0827-6
  43. Calabrò, 1989, Glucose-6-phosphate dehydrogenase (G6PD) deficiency in southern Italy: a case of G6PD A(−) associated with favism., Haematologica, 74, 71
  44. Galiano, 1990, Favism in the African type of glucose-6-phosphate dehydrogenase deficiency (A−)., Br Med J, 300, 236, 10.1136/bmj.300.6719.236 · doi:10.1136/bmj.300.6719.236
  45. Bain, 2010, A ghostly presence-G6PD deficiency., Am J Hematol, 85, 271, 10.1002/ajh.21660 · doi:10.1002/ajh.21660

Cited by

See all 104

Metadata

Authors
Pamba, A., Richardson, N. D., Carter, N., Duparc, S., Premji, Z., Tiono, A. B., & Luzzatto, L.
Affiliations
  • GlaxoSmithKline, Brentford, United Kingdom;
  • Magenta Communications Ltd, Abingdon, United Kingdom;
  • GlaxoSmithKline, Stockley Park West, United Kingdom;
  • Medicines for Malaria Venture, Geneva, Switzerland;
  • Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania;
  • Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso; and
  • Istituto Toscano Tumori (ITT), Florence, Italy
Venue
Blood
Published
2012-11-15
Volume
120
Issue
20
Pages
4123-4133
ISSN
  • 0006-4971
  • 1528-0020
Cited by
104
References
1
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase-deficient children receiving dapsone. https://app.cochat.ai/papers/10.1182/blood-2012-03-416032
The paper
Pamba, A., Richardson, N. D., Carter, N., Duparc, S., Premji, Z., Tiono, A. B., & Luzzatto, L. (2012). Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase-deficient children receiving dapsone. Blood. https://doi.org/10.1182/blood-2012-03-416032

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.